Cellvera Announces Total Sales of $100 Million in 2021 and Audited Accounts with Revenue of $50 Million

2021 sales of COVID-19 antiviral Avigan (Favipiravir) illustrate surge in demand for antiviral drugs by public health authorities with $100 million in sales

USA, April 22, 2022 /EINPresswire.com/ — Cellvera, a commercial-stage US biopharmaceutical company focused on developing and commercializing antiviral therapies to transform the lives of patients today, confirms sales of 100 million dollars for Favipiravir in 2021 and 2021 PCAOB audited accounts with $50 million in revenue and $12.1 million in EBITDA. Cellvera owns directly, or through its affiliates worldwide (excluding Japan), the exclusive rights to Avigan 200mg and Qifenda, the more potent formulation of Favipiravir. This broad-spectrum oral antiviral drug targets COVID-19 and 12 other viral families.

Cellvera generates revenue from worldwide sales of Avigan through its 50% stake in Global Response Aid (“GRA”) and direct sales from Qifenda. GRA is part of a consortium that includes Dr. Reddy’s Laboratories (NYSE: RDY), Agility (KSE/DFM: AGLTY) and FUJIFILM Toyama Chemical Co. Ltd, a subsidiary of FUJIFILM Holdings (FUJIY). Consortium members are working together to coordinate and accelerate the global development of Avigan.

The surge in demand for antiviral drugs by public health authorities is best exemplified by sales of Avigan, which have grown from a staggering start in early 2021 to $100 million by December 2021. Cellvera s expects 2022 revenues to increase by 400% as negotiations with governments continue for Avigan and Qifenda.
Avigan is already approved and used to treat COVID-19 and/or influenza in seven countries, including Japan, Mexico, Malaysia, Thailand, India, Indonesia and the United Arab Emirates, as part of various countries’ strategy to prevent the spread of COVID-19, treat those infected, reduce community transmission and reduce hospitalization rates. Many other countries buy the drug under compassionate use programs, including the UK, Greece, Hungary and Saudi Arabia. The advantage of oral antiviral treatments is that they fight COVID-19 in the community rather than in a hospital setting. Antivirals can safely and effectively speed recovery from early onset COVID-19, shorten the duration of patients’ viral load, and reduce the ability of the virus to spread, by addressing the three key parameters that the coronavirus is measured against infection, hospitalization and death.

There is an increase in expected sales precipitated by further regulatory approvals and government purchases of Avigan and Qifenda. This is coupled with the oral route of administration, hailed as a game changer for home COVID-19 treatments. This is particularly important given the increase in Omicron infections and the appearance of new variants.

Commenting on its audited revenues, Cellvera’s Chief Financial Officer, Alessandro Gadotti, said: “We are pleased with our performance in 2021 and expect a strong revenue trajectory for 2022. The surge in demand for Avigan and Qifenda reflects the evolution of the strategic approach of how health authorities aim to suppress the pandemic, and we now know that COVID-19 will not be eradicated in the short term. Gadotti continued, “We are ramping up production capacity to meet projected future demand from COVID-19 and to prepare for the threat of future pandemics. Discussions with governments are ongoing and we are working to further strengthen the development of the drug through a series of planned clinical trials. The cascade of new regulatory approvals and large-scale operations will strengthen our position over the next 12 months, setting us up for significant growth.

ABOUT FAVIPIRAVIR
Favipiravir, discovered and developed by FUJIFILM, was first approved under the brand name Avigan® by regulatory authorities in Japan in 2014 as a potent broad-spectrum antiviral treatment for influenza. This antiviral drug is effective against 12 families of viruses, including coronaviruses (COVID, MERS, SARS), filoviruses (EBOLA, MARBURG), flaviviruses (ZIKA, WEST NILE, DENGUE), RABIES, NOROVIRUS and many others. others. Favipiravir works by inhibiting a viral enzyme called RNA polymerase, preventing viral replication in human cells. Favipiravir has potent antiviral activity against single-stranded RNA viruses, including coronaviruses. It is the protein responsible for the “construction” of viral proteins. Favipiravir can target the protein needed for the coronavirus to replicate, which stops the virus from copying itself.

About Cellvera:
Cellvera is a biopharmaceutical company focused on the discovery, development and commercialization of oral therapies and monitoring tools to address the unmet medical needs of patients with life-threatening viral diseases.
Leveraging the company’s deep understanding of antiviral drug development, nucleotide chemistry, biology, biochemistry and virology, Cellvera has built a nucleotide prodrug platform to develop novel product candidates to treat viruses at single-stranded ribonucleic acid, or ssRNA, which are a prevalent cause of viral diseases.
Currently, Cellvera is focused on the clinical and commercial development of orally available, potent and selective nucleotide prodrugs for difficult-to-treat and life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). , the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).
Led to discover. The Cellvera team includes PhDs in computational biology, biochemistry and chemistry, as well as seasoned software engineers.

About Global Response Aid (GRA)
Agility (KSE/DFM: AGLTY), one of the world’s leading logistics companies, and CELLVERA, an innovative pharmaceutical research, development and commercialization company based in Dubai, have established Global Response Aid (GRA) to address the market challenges created by COVID-19. pandemic and other public health threats. GRA provides innovative and effective healthcare solutions through a range of pharmaceutical products and technology platforms. He works closely with governments, regulatory authorities, hospitals, clinics, healthcare providers, life science companies, NGOs and public institutions to develop strategies to enable them to meet the challenges of public health.
For more information: www.globalresponseaid.com

About FUJIFILM
FUJIFILM Corporation, Tokyo, Japan is one of the main operating companies of FUJIFILM Holdings Corporation. The company brings cutting-edge solutions to a wide range of global industries by leveraging its deep knowledge and core technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to various fields including healthcare, graphics systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the fiscal year ended March 31, 2020, the company had worldwide revenue of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.

For more information, holdings.fujifilm.com

Marie-O-Brien
Cellvera
+971 50 116 4708
write to us here

About Margie Peters

Check Also

My day: Grainne Hughes, Almac Pharma Services

At 8am, I’m in my car and already halfway from the office to Almac’s headquarters …